Enliven Therapeutics, Inc.
ELVN
$19.09
$0.351.87%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Total Cash And Short-Term Investments | 289.56M | 313.44M | 291.83M | 312.39M | 320.50M |
| Total Receivables | -- | -- | -- | -- | -- |
| Inventory | -- | -- | -- | -- | -- |
| Prepaid Expenses | 4.76M | 4.63M | 5.11M | 5.68M | 6.64M |
| Finance Division Loans and Leases Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Current Assets | -- | -- | -- | -- | -- |
| Other Current Assets | -- | 54.00K | 54.00K | 54.00K | 10.05M |
| Total Current Assets | 294.32M | 318.13M | 297.00M | 318.13M | 337.20M |
|
|
|||||
| Total Current Assets | 294.32M | 318.13M | 297.00M | 318.13M | 337.20M |
| Net Property, Plant & Equipment | 1.06M | 458.00K | 630.00K | 791.00K | 924.00K |
| Long-term Investments | -- | -- | -- | -- | -- |
| Goodwill | -- | -- | -- | -- | -- |
| Total Other Intangibles | -- | -- | -- | -- | -- |
| Finance Div Loans & Leases LT | -- | -- | -- | -- | -- |
| Total Finance Div Other LT Assets | -- | -- | -- | -- | -- |
| Total Other Assets | 7.20M | 7.18M | 7.80M | 8.13M | 4.65M |
| Total Assets | 302.57M | 325.76M | 305.43M | 327.04M | 342.78M |
|
|
|||||
| Total Accounts Payable | 1.56M | 1.34M | 1.02M | 1.08M | 2.73M |
| Total Accrued Expenses | 11.90M | 14.37M | 15.71M | 11.36M | 11.61M |
| Short-term Debt | -- | -- | -- | -- | -- |
| Current Portion of Long-Term Debt/Capital Leases | -- | -- | -- | -- | -- |
| Finance Division Debt Current | 365.00K | -- | 85.00K | 169.00K | 252.00K |
| Total Finance Division Other Current Liabilities | 146.00K | 204.00K | 216.00K | 9.49M | 10.45M |
| Total Other Current Liabilities | 146.00K | 204.00K | 216.00K | 9.49M | 10.45M |
| Total Current Liabilities | 13.97M | 15.92M | 17.03M | 22.11M | 25.03M |
|
|
|||||
| Total Current Liabilities | 13.97M | 15.92M | 17.03M | 22.11M | 25.03M |
| Long-Term Debt | -- | -- | -- | -- | -- |
| Short-term Debt | -- | -- | -- | -- | -- |
| Capital Leases | 302.00K | -- | -- | -- | -- |
| Finance Division Debt Non Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Non Current Liabilities | -- | -- | -- | -- | -- |
| Total Other Liabilities | -- | -- | -- | 6.00K | 34.00K |
| Total Liabilities | 14.27M | 15.92M | 17.03M | 22.11M | 25.07M |
|
|
|||||
| Common Stock & APIC | 560.33M | 553.26M | 508.45M | 502.21M | 494.95M |
| Retained Earnings | -272.02M | -243.47M | -220.29M | -197.14M | -177.19M |
| Treasury Stock & Other | -16.00K | 55.00K | 242.00K | -139.00K | -53.00K |
| Total Common Equity | 288.30M | 309.85M | 288.40M | 304.93M | 317.71M |
|
|
|||||
| Preferred Stock Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Non Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Convertible | -- | -- | -- | -- | -- |
| Preferred Stock, Others | -- | -- | -- | -- | -- |
| Total Preferred Equity | -- | -- | -- | -- | -- |
|
|
|||||
| Total Common Equity | 288.30M | 309.85M | 288.40M | 304.93M | 317.71M |
| Total Preferred Equity | -- | -- | -- | -- | -- |
| Total Minority Interest | -- | -- | -- | -- | -- |
| Total Equity | 288.30M | 309.85M | 288.40M | 304.93M | 317.71M |
|
|
|||||